Ignite Creation Date:
2024-05-06 @ 7:13 AM
Last Modification Date:
2024-10-26 @ 11:46 AM
Study NCT ID:
NCT02492620
Status:
COMPLETED
Last Update Posted:
2018-08-01
First Post:
2015-06-30
Brief Title:
Ferric Citrate for the Transition From CKD Stage 45 to CKD Stage 5D
Sponsor:
Denver Nephrologists PC
Organization:
Denver Nephrologists PC
Study Overview
Official Title:
A Two-Arm Open-Label Standard of Care Control Evaluation of Ferric Citrate for the Transition From Chronic Kidney Disease Stage 45 to Chronic Kidney Stage 5D
Status:
COMPLETED
Status Verified Date:
2018-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
05D
Brief Summary:
It is the investigators hypothesis that participants treated with Ferric Citrate FC during the non-dialysis CKD stage 45 with sufficient duration prior to initiating RRT will result in improved biochemical control of anemia Hb TSAT and mineral metabolism P FGF23 and furthermore will result in a reduced need for ESA and intravenous iron The investigators further hypothesize that effective treatment of anemia and mineral metabolism with FC in the pre-dialysis and transition period will result in improved physical functioning reduced hospitalization and reduced total cost of care when compared to participants receiving contemporaneously provided standard of care therapy
Detailed Description:
This is an up to 50 week phase 3 clinical trial in patients with estimated glomerular filtration rate eGFR 20 mlmin173m2 It will be comprised of an up to 36-week non-dialysis period NDP or until such time as subjects require renal replacement therapy RRT with dialysis when they will immediately roll into a 12-week dialysis period DP The study will consist of up to 16 clinic visits over a maximum period of 50 weeks There will be a screening period of up to 14 days after which subjects will be randomized into the NDP in a 21 ratio to receive either FC n150 or SOC n75 Each eligible participant will be randomized to either fixed dose open-label ferric citrate FC or standard of care SOC treatment Participants randomized to SOC will receive care directed by their primary nephrologist throughout the study duration with the only restriction being that they cannot receive treatment with FC during the NDP or DP Participants randomized to FC will receive it throughout the study duration
220 participants were screened to randomize 200 subjects 21 FCSOC into the NDP It is anticipated that 35-45 of participants will reach the dialysis period DP during the 36 week follow up Participants who initiate RRT with dialysis will enter the Dialysis Period DP during which those participants previously assigned to ferric citrate will continue to receive open-label ferric citrate and those previously assigned to SOC will receive open-label non-FC phosphate binders at the discretion of their treating physician During this period all participants will be treated to standard of care guidelines which suggest that if serum phosphate is above the upper limit of normal 45 mgdL it should be reduced During the DP dose of P binders use of ESA intravenous iron and blood transfusions will be at the discretion of the primary treating nephrologist Participants assigned to the SOC treatment arm may not receive FC at any point during the study
Only participants that begin permanent RRT with dialysis will be eligible to enter the 12 week DP Participants that do not begin RRT after 9 months participation in the NDP will be deemed to have reach the end of study and have end of study procedures performed
220 participants were screened to randomize 200 subjects 21 FCSOC into the NDP It is anticipated that 35-45 of participants will reach the dialysis period DP during the 36 week follow up Participants who initiate RRT with dialysis will enter the Dialysis Period DP during which those participants previously assigned to ferric citrate will continue to receive open-label ferric citrate and those previously assigned to SOC will receive open-label non-FC phosphate binders at the discretion of their treating physician During this period all participants will be treated to standard of care guidelines which suggest that if serum phosphate is above the upper limit of normal 45 mgdL it should be reduced During the DP dose of P binders use of ESA intravenous iron and blood transfusions will be at the discretion of the primary treating nephrologist Participants assigned to the SOC treatment arm may not receive FC at any point during the study
Only participants that begin permanent RRT with dialysis will be eligible to enter the 12 week DP Participants that do not begin RRT after 9 months participation in the NDP will be deemed to have reach the end of study and have end of study procedures performed
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None